# SIN3A

Source: https://onco.cc/targets/sin3a/  
OnCo record `sin3a` (Target). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

SIN3A (Paired amphipathic helix protein Sin3a) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Non-Hodgkin lymphoma, Diffuse large B-cell lymphoma and Burkitt lymphoma.

## Summary

Acts as a transcriptional repressor. Corepressor for REST. Interacts with MXI1 to repress MYC responsive genes and antagonise MYC oncogenic activities.

CIViC holds 2 clinical evidence items and 0 assertions across 1 variant. IntOGen calls it a driver in 2 cohorts (0 activating, 2 loss-of-function), covering Burkitt Lymphoma, Non-Hodgkin Lymphoma.

## Fields

- Kind: Target
- Last checked: 2026-09-23
- Also known as: SIN3 transcription regulator family member A; Paired amphipathic helix protein Sin3a; KIAA0700; DKFZP434K2235
- Tags: cancer-genes-wave
- Symbol: SIN3A
- Class: tumor-suppressor
- Biology: Acts as a transcriptional repressor. Corepressor for REST. Interacts with MXI1 to repress MYC responsive genes and antagonise MYC oncogenic activities. Also interacts with MXD1-MAX heterodimers to repress transcription by tethering SIN3A to DNA. Acts cooperatively with OGT to repress transcription in parallel with histone deacetylation. Involved in the control of the circadian rhythms. Location: Nucleus; Nucleus, nucleolus (UniProt). Locus 15q24.2 (HGNC).
- Where found: Non-Hodgkin lymphoma: IntOGen driver in 1 cohort (NHL); Diffuse large B-cell lymphoma: CIViC evidence names this disease; Burkitt lymphoma: CIViC evidence names this disease; IntOGen driver in 1 cohort (BL)

## Notes

- Written by scripts/fetch-cancer-genes.ts from CIViC, Open Targets, IntOGen, HGNC and UniProt; the function text is UniProt's, condensed and in UK spelling. Roles: IntOGen calls it a loss-of-function (LoF) driver in 2 cohorts; CIViC holds 2 clinical evidence items on its variants. Evidence tier "clinical-evidence" is the strongest of those signals.
- Prevalence not recorded: none of the sources gives a positivity rate.

## Sources

- HGNC HGNC:19353: https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:19353
- UniProt Q96ST3: https://www.uniprot.org/uniprotkb/Q96ST3/entry
- NCBI Gene 25942: https://www.ncbi.nlm.nih.gov/gene/25942
- Ensembl ENSG00000169375: https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000169375

## Connected records

- collections: [CIViC](https://onco.cc/collections/civic/), [IntOGen](https://onco.cc/collections/intogen/)
- cancers: [Burkitt lymphoma](https://onco.cc/cancers/burkitt-lymphoma/), [Diffuse large B-cell lymphoma](https://onco.cc/cancers/dlbcl/), [Non-Hodgkin lymphoma (all types)](https://onco.cc/cancers/non-hodgkin-lymphoma/)

---
JSON: https://onco.cc/api/v1/entities/sin3a.json